 SOUTH SAN FRANCISCO, Calif., April 08, 2021 GLOBE NEWSWIRE -- Global Blood Therapeutics, Inc. GBT NASDAQ: GBT today announced The Lancet Haematology has published the complete analysis of 72-week data from the Phase 3 HOPE Study of Oxbryta voxelotor tablets in patients with sickle cell disease SCD. The results showed significant and sustained improvement in hemoglobin levels, reduction in hemolysis and improved overall health status in patients treated with Oxbryta. These findings support the long-term use of Oxbryta to reduce hemolytic anemia and hemolysis in SCD, potentially mitigating life-threatening complications of the condition. 